These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15675725)

  • 1. Is levodopa toxic?
    Müller T; Hefter H; Hueber R; Jost WH; Leenders KL; Odin P; Schwarz J
    J Neurol; 2004 Sep; 251 Suppl 6():VI/44-6. PubMed ID: 15675725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa and the progression of Parkinson's disease.
    Morgan J; Sethi KD
    Curr Neurol Neurosci Rep; 2005 Jul; 5(4):261-2. PubMed ID: 15987608
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa neurotoxicity: experimental studies versus clinical relevance.
    Jenner PG; Brin MF
    Neurology; 1998 Jun; 50(6 Suppl 6):S39-43; discussion S44-8. PubMed ID: 9633686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease.
    Müller T; Werne B; Fowler B; Kuhn W
    Lancet; 1999 Jul; 354(9173):126-7. PubMed ID: 10408491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?
    Postuma RB; Lang AE
    Neurology; 2004 Sep; 63(5):886-91. PubMed ID: 15365141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor complications, levodopa metabolism and progression of Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2011 Jul; 7(7):847-55. PubMed ID: 21480824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
    Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
    Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment.
    Hirsch EC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S115-20; discussion S120-1. PubMed ID: 10762138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.
    Müller T; Renger K; Kuhn W
    Arch Neurol; 2004 May; 61(5):657-60. PubMed ID: 15148140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa: effect on cell death and the natural history of Parkinson's disease.
    Olanow CW
    Mov Disord; 2015 Jan; 30(1):37-44. PubMed ID: 25502620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease.
    Müller T
    Expert Rev Neurother; 2013 Jun; 13(6):707-18. PubMed ID: 23739007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does levodopa accelerate Parkinson's disease?
    Simuni T; Stern MB
    Drugs Aging; 1999 Jun; 14(6):399-408. PubMed ID: 10408739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
    Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?
    Ziv I; Zilkha-Falb R; Offen D; Shirvan A; Barzilai A; Melamed E
    Mov Disord; 1997 Jan; 12(1):17-23. PubMed ID: 8990049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
    Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
    Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease.
    Gao HM; Jiang J; Wilson B; Zhang W; Hong JS; Liu B
    J Neurochem; 2002 Jun; 81(6):1285-97. PubMed ID: 12068076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-dopaminergic drug treatment of Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2001 Apr; 2(4):557-72. PubMed ID: 11336607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson's patients?
    Qureshi GA; Qureshi AA; Devrajani BR; Chippa MA; Syed SA
    CNS Neurol Disord Drug Targets; 2008 Feb; 7(1):20-7. PubMed ID: 18289028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.